Replicel Life Sciences Stock Current Ratio
| REPCF Stock | USD 0 0 950.00% |
RepliCel Life Sciences fundamentals help investors to digest information that contributes to RepliCel Life's financial success or failures. It also enables traders to predict the movement of RepliCel Pink Sheet. The fundamental analysis module provides a way to measure RepliCel Life's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to RepliCel Life pink sheet.
RepliCel |
RepliCel Life Sciences Company Current Ratio Analysis
RepliCel Life's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current RepliCel Life Current Ratio | 0.23 X |
Most of RepliCel Life's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, RepliCel Life Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
In accordance with the recently published financial statements, RepliCel Life Sciences has a Current Ratio of 0.23 times. This is 92.1% lower than that of the Life Sciences Tools & Services sector and 96.71% lower than that of the Health Care industry. The current ratio for all United States stocks is 89.35% higher than that of the company.
RepliCel Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses RepliCel Life's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of RepliCel Life could also be used in its relative valuation, which is a method of valuing RepliCel Life by comparing valuation metrics of similar companies.RepliCel Life is currently under evaluation in current ratio category among its peers.
RepliCel Fundamentals
| Return On Asset | -1.65 | |||
| Operating Margin | (4.19) % | |||
| Current Valuation | 3.42 M | |||
| Shares Outstanding | 54.36 M | |||
| Shares Owned By Insiders | 68.42 % | |||
| Price To Earning | (1.00) X | |||
| Price To Sales | 8.35 X | |||
| Revenue | 353.74 K | |||
| Gross Profit | 353.74 K | |||
| EBITDA | (4.07 M) | |||
| Net Income | (4.07 M) | |||
| Cash And Equivalents | 228 K | |||
| Total Debt | 34.26 K | |||
| Current Ratio | 0.23 X | |||
| Book Value Per Share | (0.22) X | |||
| Cash Flow From Operations | (2.51 M) | |||
| Earnings Per Share | (0.09) X | |||
| Number Of Employees | 23 | |||
| Beta | 1.19 | |||
| Market Capitalization | 5.29 M | |||
| Total Asset | 591.79 K | |||
| Retained Earnings | (14.76 M) | |||
| Z Score | 39.0 | |||
| Net Asset | 591.79 K |
About RepliCel Life Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze RepliCel Life Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of RepliCel Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of RepliCel Life Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in RepliCel Pink Sheet
RepliCel Life financial ratios help investors to determine whether RepliCel Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in RepliCel with respect to the benefits of owning RepliCel Life security.